Inflation Reduction Act: Assessing the Impact for New Drug Development, Launch, Life Cycle Management and Loss of Exclusivity


Briggs S1, Francois C2, Auger E1, Busch A1
1Putnam, Boston, MA, USA, 2Putnam PHMR, Paris, France

Presentation Documents

OBJECTIVES: The Inflation Reduction Act (IRA) will have impact on drug development and commercialization strategy throughout the product lifecycle. This study aimed to assess the potential consequences on the different steps of the drug development process.

METHODS: We analyzed the preliminary implications of the IRA for drug development, launch, Life Cycle Management (LCM) and Loss of Exclusivity (LOE) using the Inflation Reduction Act of 2022 (H.R.5376 – 117th Congress), Congressional Budget Office “Additional Information About Prescription Drug Legislation” Report, and relevant hand desk research.

RESULTS: Drug discovery and development emphasis may shift away from small molecule drugs to biologics with longer protection from price negotiation (11 years vs. 7 years exclusion post-approval) and towards the patient population extremes (lower cost general medicine drugs less impacted by the Medicare Part D benefit redesign and orphan drugs excluded from price negotiation). For new drug launches, to counteract the shorter free pricing period that the Medicare drug price negotiation rule creates, manufacturers are expected to launch new drugs or biologics at higher prices per patient to mitigate impact on lifetime sales potential. For LCM, manufacturers may revisit the development of follow-on indications particularly those (1) for which development costs may be NPV-negative given the reduced timeframe between follow-on approval and expected price negotiation, (2) that may push drugs over the Medicare negotiation risk threshold, and (3) could invalidate orphan designation exclusions conferred by the launch indication. Finally, for LOE, as drugs with generic or biosimilar competition are negotiation-ineligible and “imminent” generic or biosimilar entry can delay negotiation eligibility, manufacturers may be less incentivized to employ legal tactics to delay biosimilar entry.

CONCLUSIONS: This qualitative analysis illustrates how the IRA can impact the drug lifecycle from early development to LOE. Further research will be needed to monitor the consequences, expected or unexpected, over time.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Health Policy & Regulatory

Topic Subcategory

Insurance Systems & National Health Care, Pricing Policy & Schemes, Public Spending & National Health Expenditures, Reimbursement & Access Policy


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now